The National Comprehensive Cancer Network (NCCN) has received a one million dollar ($1,000,000) research grant from ImmunoGen under a Research Agreement dated as of March 6, 2015 (the “Research Agreement”) to support NCCN Member Institution faculty for the performance of clinical studies with mirvetuximab soravtansine, previously known as IMGN853, in patients with ovarian, endometrial, and breast cancer. NCCN will serve as the funding organization for these grants that are available only to NCCN investigators. The following sections detail the objectives, process and requirements of this RFP, which shall be subject to the terms and conditions of the Research Agreement.

Download full funding opportunity announcement here: NCCN ImmunoGen Clinical RFP